Preprescription genotyping: Not yet ready for prime time, but getting there

Circulation

Volumn 103, Issue 12, 2001, Pages 1608-1610

  Roden, Dan M ^a   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drugs; Editorials; Genes

Indexed keywords

DNA POLYMORPHISM; DRUG INTERACTION; DRUG MECHANISM; DRUG RESPONSE; EDITORIAL; GENOTYPE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0035957261     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.12.1608     Document Type: Editorial

References (25)

1. Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure
2. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
3. Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure
4. Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy?
5. Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese
6. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans
7. Prolonged postoperative apnea with pseudocholinesterase deficiency
8. Genetic control of isoniazid metabolism in man
9. Polymorphic drug metabolism and codeine pharmacodynamics
10. Racial differences in drug response: Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites
11. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
12. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
13. Role of intestinal P-glycoprotein (mdr 1) in interpatient variation in the oral bioavailability of cyclosporine
14. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
15. Polymorphic hydroxylation of debrisoquine in man
16. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
17. Oxidation phenotype: A major determinant of metoprolol metabolism and response
18. Stereoselective disposition of carvedilol is determined by CYP2D6
19. The geneticist's approach to complex disease
20. Molecular basis of human hypertension: Role of angiotensinogen
21. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension
22. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure
23. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness